ENTR-601-44

· Entrada Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ENTR-601-44, covering 2026-03-09 to 2026-03-09. Get the full timeline:

Most recent: Clinical Trial Update: A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44 [Phase 1, Phase 2]

See pricing